Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094120
Status:
TERMINATED
Last Update Posted:
2008-01-09
First Post:
2004-10-11
Brief Title:
MSI-1256F Squalamine Lactate in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration AMD
Sponsor:
Genaera Corporation
Organization:
Genaera Corporation
Study Overview
Official Title:
Safety and Efficacy of MSI-1256F Squalamine Lactate in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration AMD
Status:
TERMINATED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Age-Related Macular Degeneration AMD is a degenerative disease of the retina that causes a progressive loss of central vision AMD is the leading cause of legal blindness among adults age 50 or older in the Western world AMD presents in two different types - dry and the more severe wet form Wet AMD is caused by the growth of abnormal blood vessels in the macula
Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with wet AMD
Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with wet AMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None